Merck chief concerned over future U.S. biopharma innovation

Merck ($MRK) CEO Kenneth Frazier has weighed in on some of the U.S. biopharmaceutical industry's most pressing issues in an opinion piece in the Wall Street Journal. He warns that weak protections on drug patents, drug pricing policies and the high cost of drug development threaten the global leadership of the U.S. biopharma industry. The op-ed calls on policymakers to take actions that would support further innovation in biopharma. Item

Suggested Articles

Fauci said the FDA has vowed not to let political pressure to approve a COVID-19 vaccine as soon as possible interfere with the regulatory process.

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.